Serious adverse events
|
Placebo |
Lixisenatide |
Total subjects affected by serious adverse events
|
|
|
subjects affected / exposed
|
669 / 3032 (22.06%) |
625 / 3031 (20.62%) |
number of deaths (all causes)
|
96 |
93 |
number of deaths resulting from adverse events
|
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
|
Adenocarcinoma Gastric
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Adenocarcinoma Of Colon
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
6 / 3031 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
Adenocarcinoma Pancreas
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Adenosquamous Cell Lung Cancer
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
B-Cell Lymphoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
B-Cell Unclassifiable Lymphoma Low Grade
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Basal Cell Carcinoma
|
|
|
subjects affected / exposed
|
5 / 3032 (0.16%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Benign Neoplasm
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Benign Renal Neoplasm
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Benign Salivary Gland Neoplasm
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Benign Small Intestinal Neoplasm
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bladder Cancer
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bladder Neoplasm
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Brain Neoplasm
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Breast Cancer
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Breast Neoplasm
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bronchial Carcinoma
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Chronic Lymphocytic Leukaemia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Clear Cell Renal Cell Carcinoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Colon Adenoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Colon Cancer
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Colon Cancer Metastatic
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Colon Cancer Recurrent
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Colon Neoplasm
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Colorectal Adenocarcinoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diffuse Large B-Cell Lymphoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Endometrial Cancer
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fibromatosis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gallbladder Cancer
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Gastric Cancer
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Gastric Cancer Stage Iv
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Glioblastoma Multiforme
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Hepatocellular Carcinoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
Iris Melanoma
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Keratoacanthoma
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lip Squamous Cell Carcinoma
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lipoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lung Adenocarcinoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Lung Cancer Metastatic
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lung Neoplasm Malignant
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lymphoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Malignant Melanoma
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Malignant Pleural Effusion
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Meningioma
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metastases To Central Nervous System
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metastases To Liver
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metastases To Lung
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metastases To Pancreas
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metastatic Pain
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Non-Small Cell Lung Cancer
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Non-Hodgkin's Lymphoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Ovarian Cancer
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Ovarian Cancer Stage Iii
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Ovarian Epithelial Cancer
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pancreatic Carcinoma
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
1 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
1 / 2 |
0 / 0 |
Pancreatic Carcinoma Metastatic
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Papillary Thyroid Cancer
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Phaeochromocytoma
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pharyngeal Cancer
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pituitary Tumour Benign
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Plasma Cell Myeloma
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Prostate Cancer
|
|
|
subjects affected / exposed
|
7 / 3032 (0.23%) |
10 / 3031 (0.33%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 10 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Prostate Cancer Metastatic
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Prostate Cancer Stage I
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Prostatic Adenoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rectal Adenocarcinoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rectal Adenoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rectal Cancer
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal Cancer
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal Cancer Metastatic
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Renal Cell Carcinoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Retroperitoneal Neoplasm
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Salivary Gland Neoplasm
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Skin Cancer
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Small Cell Lung Cancer
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Small Cell Lung Cancer Metastatic
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Small Intestine Adenocarcinoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Squamous Cell Carcinoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Squamous Cell Carcinoma Of Lung
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Squamous Cell Carcinoma Of Skin
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Testicular Neoplasm
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Transitional Cell Carcinoma
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vascular disorders
|
|
|
Accelerated Hypertension
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Aortic Dissection
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Aortic Stenosis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Aortic Thrombosis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arterial Disorder
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arterial Occlusive Disease
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arteriosclerosis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arteritis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blood Pressure Inadequately Controlled
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Circulatory Collapse
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Deep Vein Thrombosis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
5 / 3031 (0.16%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic Vascular Disorder
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Embolism
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Essential Hypertension
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Extremity Necrosis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Femoral Artery Aneurysm
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Granulomatosis With Polyangiitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemorrhage
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypertension
|
|
|
subjects affected / exposed
|
9 / 3032 (0.30%) |
5 / 3031 (0.16%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypertensive Crisis
|
|
|
subjects affected / exposed
|
13 / 3032 (0.43%) |
15 / 3031 (0.49%) |
occurrences causally related to treatment / all
|
0 / 15 |
0 / 18 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypertensive Emergency
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypotension
|
|
|
subjects affected / exposed
|
6 / 3032 (0.20%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 6 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypovolaemic Shock
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intermittent Claudication
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Leriche Syndrome
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Orthostatic Hypotension
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral Arterial Occlusive Disease
|
|
|
subjects affected / exposed
|
7 / 3032 (0.23%) |
5 / 3031 (0.16%) |
occurrences causally related to treatment / all
|
0 / 11 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral Artery Aneurysm
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral Artery Stenosis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
5 / 3031 (0.16%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral Artery Thrombosis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral Embolism
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral Ischaemia
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral Vascular Disorder
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral Venous Disease
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Shock Haemorrhagic
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vascular Occlusion
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vascular Stenosis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vasculitis Necrotising
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Venous Thrombosis Limb
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Surgical and medical procedures
|
|
|
Cardioplegia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholecystectomy
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Debridement
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hip Arthroplasty
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Implantable Defibrillator Insertion
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intraocular Lens Implant
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Knee Arthroplasty
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Leg Amputation
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral Artery Bypass
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pleurodesis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Toe Amputation
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
General disorders and administration site conditions
|
|
|
Arterial Restenosis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Asthenia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chest Discomfort
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chest Pain
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
Coronary Artery Restenosis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Death
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 3 |
Gait Disturbance
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Impaired Healing
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Implant Site Extravasation
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Inflammation
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Local Swelling
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Malaise
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Multi-Organ Failure
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
Non-Cardiac Chest Pain
|
|
|
subjects affected / exposed
|
42 / 3032 (1.39%) |
46 / 3031 (1.52%) |
occurrences causally related to treatment / all
|
0 / 48 |
0 / 52 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Oedema Peripheral
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pain
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Polyp
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pyrexia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Sudden Death
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Systemic Inflammatory Response Syndrome
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Thrombosis In Device
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vessel Puncture Site Haematoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Immune system disorders
|
|
|
Anaphylactic Reaction
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Anaphylactic Shock
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Drug Hypersensitivity
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Social circumstances
|
|
|
Joint Prosthesis User
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Reproductive system and breast disorders
|
|
|
Adenomyosis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Benign Prostatic Hyperplasia
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
5 / 3031 (0.16%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metrorrhagia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ovarian Cyst
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ovarian Cyst Ruptured
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Prostatism
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Prostatitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Prostatomegaly
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Uterine Prolapse
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vulval Ulceration
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Respiratory, thoracic and mediastinal disorders
|
|
|
Acute Pulmonary Oedema
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Acute Respiratory Distress Syndrome
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Acute Respiratory Failure
|
|
|
subjects affected / exposed
|
5 / 3032 (0.16%) |
6 / 3031 (0.20%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Asthma
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Asthmatic Crisis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bronchitis Chronic
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bronchospasm
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chronic Obstructive Pulmonary Disease
|
|
|
subjects affected / exposed
|
14 / 3032 (0.46%) |
15 / 3031 (0.49%) |
occurrences causally related to treatment / all
|
0 / 16 |
0 / 16 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cough
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dyspnoea
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
7 / 3031 (0.23%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Dyspnoea Exertional
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Epistaxis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemoptysis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemothorax
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hydrothorax
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypoxia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Interstitial Lung Disease
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
1 / 1 |
Laryngeal Stenosis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lung Disorder
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lung Infiltration
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Nasal Polyps
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Obstructive Airways Disorder
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pharyngeal Mass
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pickwickian Syndrome
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pleural Effusion
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pleurisy
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pneumonia Aspiration
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary Embolism
|
|
|
subjects affected / exposed
|
8 / 3032 (0.26%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary Hypertension
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary Mass
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary Toxicity
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Respiratory Acidosis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Respiratory Disorder
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Respiratory Distress
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Respiratory Failure
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
4 / 3031 (0.13%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Respiratory Tract Haemorrhage
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Sleep Apnoea Syndrome
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vocal Cord Disorder
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Wheezing
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Psychiatric disorders
|
|
|
Adjustment Disorder
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Alcohol Abuse
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Anxiety
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Completed Suicide
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Confusional State
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Conversion Disorder
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Depression
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Mania
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Psychogenic Seizure
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Suicidal Ideation
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Investigations
|
|
|
Alanine Aminotransferase Increased
|
|
|
subjects affected / exposed
|
7 / 3032 (0.23%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Angiogram
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blood Creatinine Increased
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blood Glucose Abnormal
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blood Glucose Fluctuation
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blood Glucose Increased
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blood Pressure Increased
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blood Sodium Decreased
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Carbohydrate Antigen 19-9 Increased
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac Pacemaker Evaluation
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Catheterisation Cardiac
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Crystal Urine Present
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Electrocardiogram Abnormal
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Glycosylated Haemoglobin Increased
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Prostatic Specific Antigen Increased
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urine Output Decreased
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Weight Decreased
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Injury, poisoning and procedural complications
|
|
|
Accidental Overdose
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Acetabulum Fracture
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Alcohol Poisoning
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Allergic Transfusion Reaction
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ankle Fracture
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arthropod Sting
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Brain Contusion
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cartilage Injury
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chest Injury
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Concussion
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Contusion
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Craniocerebral Injury
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fall
|
|
|
subjects affected / exposed
|
7 / 3032 (0.23%) |
7 / 3031 (0.23%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Femoral Neck Fracture
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Femur Fracture
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fibula Fracture
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Foot Fracture
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Forearm Fracture
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Foreign Body
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gun Shot Wound
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Hand Fracture
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Head Injury
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hip Fracture
|
|
|
subjects affected / exposed
|
8 / 3032 (0.26%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Humerus Fracture
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Incision Site Haematoma
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Incisional Hernia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Joint Dislocation
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Joint Injury
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ligament Rupture
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ligament Sprain
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Limb Injury
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lower Limb Fracture
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lumbar Vertebral Fracture
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Medication Error
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Meniscus Injury
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Multiple Injuries
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post Procedural Complication
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post Procedural Discharge
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post Procedural Haematoma
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post Procedural Haemorrhage
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Postoperative Fever
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Postoperative Thoracic Procedure Complication
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Procedural Pain
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pubis Fracture
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Radius Fracture
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rib Fracture
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Scar
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Scrotal Haematoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Skull Fracture
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Soft Tissue Injury
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Spinal Fracture
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Sports Injury
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Subdural Haematoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Subdural Haemorrhage
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Tibia Fracture
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Toxicity To Various Agents
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ulna Fracture
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vascular Pseudoaneurysm
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Wound Haemorrhage
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac disorders
|
|
|
Angina Pectoris
|
|
|
subjects affected / exposed
|
23 / 3032 (0.76%) |
23 / 3031 (0.76%) |
occurrences causally related to treatment / all
|
0 / 24 |
0 / 27 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arrhythmia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arteriosclerosis Coronary Artery
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atrial Fibrillation
|
|
|
subjects affected / exposed
|
30 / 3032 (0.99%) |
23 / 3031 (0.76%) |
occurrences causally related to treatment / all
|
0 / 37 |
0 / 28 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atrial Flutter
|
|
|
subjects affected / exposed
|
5 / 3032 (0.16%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atrial Tachycardia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atrioventricular Block
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atrioventricular Block Complete
|
|
|
subjects affected / exposed
|
8 / 3032 (0.26%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atrioventricular Block First Degree
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atrioventricular Block Second Degree
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bifascicular Block
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bradycardia
|
|
|
subjects affected / exposed
|
5 / 3032 (0.16%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac Arrest
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Cardio-Respiratory Arrest
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coronary Artery Disease
|
|
|
subjects affected / exposed
|
5 / 3032 (0.16%) |
4 / 3031 (0.13%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coronary Artery Occlusion
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypertensive Heart Disease
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intracardiac Thrombus
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ischaemic Cardiomyopathy
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Left Ventricular Dysfunction
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Mitral Valve Incompetence
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Myocardial Ischaemia
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Myocarditis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Palpitations
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pericardial Effusion
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pericardial Haemorrhage
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pericarditis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Sick Sinus Syndrome
|
|
|
subjects affected / exposed
|
5 / 3032 (0.16%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Supraventricular Tachycardia
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Tachyarrhythmia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Tachycardia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Trifascicular Block
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ventricular Extrasystoles
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ventricular Tachycardia
|
|
|
subjects affected / exposed
|
8 / 3032 (0.26%) |
9 / 3031 (0.30%) |
occurrences causally related to treatment / all
|
0 / 13 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Nervous system disorders
|
|
|
Amyotrophic Lateral Sclerosis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Aphasia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Brain Injury
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Carotid Artery Dissection
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Carotid Artery Occlusion
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Carotid Artery Stenosis
|
|
|
subjects affected / exposed
|
6 / 3032 (0.20%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Carpal Tunnel Syndrome
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cerebral Haemorrhage
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cerebral Ischaemia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cervical Radiculopathy
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cognitive Disorder
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Convulsion
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Depressed Level Of Consciousness
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic Neuropathy
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dizziness
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Epilepsy
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Essential Tremor
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Facial Nerve Disorder
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Facial Paresis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Headache
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hemiparesis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypoaesthesia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypoglycaemic Unconsciousness
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
1 / 3 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypoxic-Ischaemic Encephalopathy
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intracranial Haematoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Loss Of Consciousness
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lumbar Radiculopathy
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Migraine
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Morton's Neuralgia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Multiple Sclerosis Relapse
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Neuropathy Peripheral
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Optic Neuritis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Paraplegia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral Sensorimotor Neuropathy
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Presyncope
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
4 / 3031 (0.13%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Psychomotor Hyperactivity
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pyramidal Tract Syndrome
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Radial Nerve Palsy
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Radicular Pain
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Radiculitis Lumbosacral
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Sciatica
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Syncope
|
|
|
subjects affected / exposed
|
16 / 3032 (0.53%) |
16 / 3031 (0.53%) |
occurrences causally related to treatment / all
|
1 / 17 |
0 / 17 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Transient Ischaemic Attack
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Trigeminal Neuralgia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Viith Nerve Paralysis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vith Nerve Paralysis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blood and lymphatic system disorders
|
|
|
Anaemia
|
|
|
subjects affected / exposed
|
9 / 3032 (0.30%) |
8 / 3031 (0.26%) |
occurrences causally related to treatment / all
|
1 / 9 |
0 / 12 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coagulopathy
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemorrhagic Anaemia
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Increased Tendency To Bruise
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Iron Deficiency Anaemia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Nephrogenic Anaemia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Neutropenia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Normochromic Normocytic Anaemia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pernicious Anaemia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Thrombocytopenia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ear and labyrinth disorders
|
|
|
Deafness Neurosensory
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Sudden Hearing Loss
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vertigo
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vertigo Labyrinthine
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vertigo Positional
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Eye disorders
|
|
|
Amaurosis Fugax
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Angle Closure Glaucoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arteriosclerotic Retinopathy
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blindness Unilateral
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cataract
|
|
|
subjects affected / exposed
|
5 / 3032 (0.16%) |
4 / 3031 (0.13%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cataract Nuclear
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic Eye Disease
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic Retinal Oedema
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Glaucoma
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Open Angle Glaucoma
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ophthalmoplegia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Retinal Detachment
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Uveitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vitreous Haemorrhage
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastrointestinal disorders
|
|
|
Abdominal Adhesions
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal Distension
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal Hernia
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal Incarcerated Hernia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal Pain
|
|
|
subjects affected / exposed
|
7 / 3032 (0.23%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
3 / 7 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal Pain Upper
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal Rigidity
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal Wall Haemorrhage
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Anal Fistula
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chronic Gastritis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Colitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Constipation
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Crohn's Disease
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic Gastroparesis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diarrhoea
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
1 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diverticular Perforation
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diverticulum
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Duodenal Ulcer
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
4 / 3031 (0.13%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Duodenal Ulcer Haemorrhage
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Duodenitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dyspepsia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dysphagia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Epigastric Discomfort
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Faecal Vomiting
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Food Poisoning
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastric Disorder
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastric Polyps
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastric Ulcer
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastric Ulcer Haemorrhage
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastritis
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
7 / 3031 (0.23%) |
occurrences causally related to treatment / all
|
1 / 4 |
3 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastritis Erosive
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastritis Haemorrhagic
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastroduodenitis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastroduodenitis Haemorrhagic
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastrointestinal Disorder
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastrointestinal Haemorrhage
|
|
|
subjects affected / exposed
|
6 / 3032 (0.20%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
1 / 6 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastrooesophageal Reflux Disease
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gingival Bleeding
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haematemesis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemorrhoidal Haemorrhage
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemorrhoids
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ileus
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Impaired Gastric Emptying
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Inguinal Hernia
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
5 / 3031 (0.16%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intestinal Haemorrhage
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intestinal Ischaemia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Intestinal Obstruction
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Large Intestine Perforation
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Large Intestine Polyp
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lower Gastrointestinal Haemorrhage
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Mallory-Weiss Syndrome
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Melaena
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Nausea
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
2 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Obstruction Gastric
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Oesophageal Ulcer
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Oesophagitis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pancreatitis
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
1 / 3 |
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pancreatitis Acute
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pancreatitis Chronic
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peritoneal Haemorrhage
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rectal Haemorrhage
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Small Intestinal Ulcer Haemorrhage
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Umbilical Hernia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Umbilical Hernia, Obstructive
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Upper Gastrointestinal Haemorrhage
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
4 / 3031 (0.13%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Vomiting
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hepatobiliary disorders
|
|
|
Bile Duct Stone
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholangitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholecystitis
|
|
|
subjects affected / exposed
|
5 / 3032 (0.16%) |
9 / 3031 (0.30%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholecystitis Acute
|
|
|
subjects affected / exposed
|
7 / 3032 (0.23%) |
10 / 3031 (0.33%) |
occurrences causally related to treatment / all
|
1 / 7 |
0 / 10 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholecystitis Chronic
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholelithiasis
|
|
|
subjects affected / exposed
|
6 / 3032 (0.20%) |
13 / 3031 (0.43%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 13 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholestasis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Drug-Induced Liver Injury
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gallbladder Polyp
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hepatic Cirrhosis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hepatic Function Abnormal
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hepatitis Acute
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ischaemic Hepatitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Liver Injury
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Skin and subcutaneous tissue disorders
|
|
|
Diabetic Foot
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
8 / 3031 (0.26%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Eczema
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyperhidrosis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pruritus Generalised
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Psoriasis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Skin Ulcer
|
|
|
subjects affected / exposed
|
10 / 3032 (0.33%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Swelling Face
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urticaria
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal and urinary disorders
|
|
|
Calculus Bladder
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Calculus Ureteric
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Calculus Urinary
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haematuria
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hydronephrosis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Nephrolithiasis
|
|
|
subjects affected / exposed
|
8 / 3032 (0.26%) |
7 / 3031 (0.23%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Nephropathy
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Nephropathy Toxic
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal Artery Stenosis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal Colic
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal Failure
|
|
|
subjects affected / exposed
|
5 / 3032 (0.16%) |
6 / 3031 (0.20%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Renal Failure Acute
|
|
|
subjects affected / exposed
|
20 / 3032 (0.66%) |
20 / 3031 (0.66%) |
occurrences causally related to treatment / all
|
0 / 21 |
0 / 20 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Renal Failure Chronic
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
6 / 3031 (0.20%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Renal Impairment
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urethral Meatus Stenosis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urinary Bladder Haemorrhage
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urinary Retention
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Endocrine disorders
|
|
|
Goitre
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyperparathyroidism
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyperthyroidism
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Musculoskeletal and connective tissue disorders
|
|
|
Arthralgia
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arthritis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Back Pain
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
4 / 3031 (0.13%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bone Pain
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coccydynia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dupuytren's Contracture
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fasciitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Foot Deformity
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fracture Malunion
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemarthrosis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intervertebral Disc Protrusion
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Joint Instability
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lumbar Spinal Stenosis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Musculoskeletal Chest Pain
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Musculoskeletal Discomfort
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Musculoskeletal Pain
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Myalgia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteitis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteoarthritis
|
|
|
subjects affected / exposed
|
7 / 3032 (0.23%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pain In Extremity
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pain In Jaw
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Periarthritis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rhabdomyolysis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rheumatoid Arthritis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rotator Cuff Syndrome
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Spinal Column Stenosis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Spinal Osteoarthritis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Systemic Lupus Erythematosus
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Trigger Finger
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Infections and infestations
|
|
|
Abdominal Abscess
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal Sepsis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Abdominal Wall Infection
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abscess Limb
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Amoebic Dysentery
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Anal Abscess
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Appendicitis
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 3 |
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Appendicitis Perforated
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arthritis Infective
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bacteraemia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bacterial Pyelonephritis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bone Abscess
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bronchitis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
5 / 3031 (0.16%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bronchitis Bacterial
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bronchitis Viral
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bronchopneumonia
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
6 / 3031 (0.20%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Burn Infection
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Carbuncle
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cat Scratch Disease
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cellulitis
|
|
|
subjects affected / exposed
|
18 / 3032 (0.59%) |
17 / 3031 (0.56%) |
occurrences causally related to treatment / all
|
0 / 20 |
1 / 18 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chronic Hepatitis B
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chronic Hepatitis C
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chronic Sinusitis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Clostridium Difficile Colitis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Colonic Abscess
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dengue Fever
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Device Related Infection
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic Foot Infection
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diarrhoea Infectious
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diverticulitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Empyema
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Endocarditis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Erysipelas
|
|
|
subjects affected / exposed
|
7 / 3032 (0.23%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gallbladder Abscess
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gangrene
|
|
|
subjects affected / exposed
|
7 / 3032 (0.23%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastritis Viral
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastroenteritis
|
|
|
subjects affected / exposed
|
9 / 3032 (0.30%) |
13 / 3031 (0.43%) |
occurrences causally related to treatment / all
|
0 / 10 |
1 / 13 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastroenteritis Clostridial
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastroenteritis Viral
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastrointestinal Infection
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Groin Abscess
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
H1n1 Influenza
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haematoma Infection
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Helicobacter Gastritis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Infected Bites
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Infected Skin Ulcer
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Infective Exacerbation Of Chronic Obstructive Airways Disease
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Influenza
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Klebsiella Sepsis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Liver Abscess
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lobar Pneumonia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Localised Infection
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lower Respiratory Tract Infection
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Lung Infection
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Mediastinitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Meningitis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Mycobacterial Infection
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Nail Bed Infection
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Nasopharyngitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteomyelitis
|
|
|
subjects affected / exposed
|
9 / 3032 (0.30%) |
4 / 3031 (0.13%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteomyelitis Acute
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteomyelitis Chronic
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteomyelitis Fungal
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Otitis Media Chronic
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Paraspinal Abscess
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Paronychia
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peritonitis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pilonidal Cyst
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pleurisy Viral
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pneumonia
|
|
|
subjects affected / exposed
|
51 / 3032 (1.68%) |
36 / 3031 (1.19%) |
occurrences causally related to treatment / all
|
0 / 59 |
0 / 36 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
Pneumonia Bacterial
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post Procedural Infection
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Postoperative Wound Infection
|
|
|
subjects affected / exposed
|
5 / 3032 (0.16%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Psoas Abscess
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary Sepsis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Pulmonary Tuberculosis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Puncture Site Abscess
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pyelonephritis
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pyelonephritis Acute
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pyelonephritis Chronic
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal Abscess
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Respiratory Tract Infection
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
6 / 3031 (0.20%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Scrotal Abscess
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Sepsis
|
|
|
subjects affected / exposed
|
10 / 3032 (0.33%) |
8 / 3031 (0.26%) |
occurrences causally related to treatment / all
|
0 / 11 |
1 / 8 |
deaths causally related to treatment / all
|
0 / 3 |
1 / 4 |
Septic Shock
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
Soft Tissue Infection
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Staphylococcal Infection
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Staphylococcal Osteomyelitis
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Subcutaneous Abscess
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Subdiaphragmatic Abscess
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Tick-Borne Fever
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Tooth Abscess
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Toxoplasmosis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Upper Respiratory Tract Infection
|
|
|
subjects affected / exposed
|
3 / 3032 (0.10%) |
3 / 3031 (0.10%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urinary Tract Infection
|
|
|
subjects affected / exposed
|
19 / 3032 (0.63%) |
18 / 3031 (0.59%) |
occurrences causally related to treatment / all
|
0 / 22 |
0 / 19 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urosepsis
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Viral Corneal Ulcer
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Viral Infection
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Wound Infection
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metabolism and nutrition disorders
|
|
|
Decreased Appetite
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dehydration
|
|
|
subjects affected / exposed
|
2 / 3032 (0.07%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetes Mellitus Inadequate Control
|
|
|
subjects affected / exposed
|
18 / 3032 (0.59%) |
8 / 3031 (0.26%) |
occurrences causally related to treatment / all
|
0 / 18 |
0 / 11 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic Ketoacidosis
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Diabetic Metabolic Decompensation
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Electrolyte Imbalance
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gout
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyperglycaemia
|
|
|
subjects affected / exposed
|
7 / 3032 (0.23%) |
4 / 3031 (0.13%) |
occurrences causally related to treatment / all
|
0 / 7 |
1 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyperglycaemic Hyperosmolar Nonketotic Syndrome
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyperkalaemia
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
5 / 3031 (0.16%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypocalcaemia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypoglycaemia
|
|
|
subjects affected / exposed
|
10 / 3032 (0.33%) |
5 / 3031 (0.16%) |
occurrences causally related to treatment / all
|
3 / 11 |
4 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypokalaemia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
2 / 3031 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyponatraemia
|
|
|
subjects affected / exposed
|
4 / 3032 (0.13%) |
5 / 3031 (0.16%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypovolaemia
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Malnutrition
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metabolic Acidosis
|
|
|
subjects affected / exposed
|
0 / 3032 (0.00%) |
1 / 3031 (0.03%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Obesity
|
|
|
subjects affected / exposed
|
1 / 3032 (0.03%) |
0 / 3031 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |